These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 446410)

  • 21. Serotonergic stimulation of prolactin release in the young turkey (Meleagris gallopavo).
    Fehrer SC; Silsby JL; El Halawani ME
    Gen Comp Endocrinol; 1983 Dec; 52(3):400-8. PubMed ID: 6230284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolactin and luteinizing hormone levels of prelaying, laying and postlaying turkey hens following central administration of serotonin and peripheral administration of quipazine maleate.
    Hargis BM; Burke WH
    Gen Comp Endocrinol; 1984 Jul; 55(1):12-9. PubMed ID: 6235145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A serotonin agonist-antagonist reversible effect on Na+-K+-ATPase activity in the developing rat brain.
    Hernández RJ
    Dev Neurosci; 1982; 5(4):326-31. PubMed ID: 6291893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of midbrain raphe lesion or 5,7-dihydroxytryptamine treatment on the prolactin-releasing action of quipazine and D-fenfluramine in rats.
    Quattrone A; Schettini G; di Renzo G; Tedeschi G; Preziosi P
    Brain Res; 1979 Sep; 174(1):71-9. PubMed ID: 487124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of quipazine and D-fenfluramine, two serotonin-like drugs, on TSH secretion in basal and cold stimulated conditions in the rat.
    Di Renzo GF; Quattrone A; Schettini G; Preziosi P
    Life Sci; 1978 Jun; 22(21):1879-85. PubMed ID: 672433
    [No Abstract]   [Full Text] [Related]  

  • 26. A possible interaction of quipazine with central dopamine structures.
    Grabowska M; Antkiewicz L; Michaluk J
    J Pharm Pharmacol; 1974 Jan; 26(1):74-6. PubMed ID: 4150944
    [No Abstract]   [Full Text] [Related]  

  • 27. [Excellence of quipazine in the characterization of serotoninergic receptors and mechanisms].
    Hong E
    Gac Med Mex; 1982 Apr; 118(4):158-64. PubMed ID: 7117731
    [No Abstract]   [Full Text] [Related]  

  • 28. Serotoninergic regulation of corticosterone secretion in domestic fowl.
    Cheung A; Hall TR; Harvey S
    J Endocrinol; 1987 May; 113(2):159-65. PubMed ID: 3585229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of somatostatin on the secretion of thyrotropin and prolactin.
    Vale W; Rivier C; Brazeau P; Guillemin R
    Endocrinology; 1974 Oct; 95(4):968-77. PubMed ID: 4213073
    [No Abstract]   [Full Text] [Related]  

  • 30. Blockade of 5-hydroxytryptamine (5-HT) receptors by quipazine [proceedings].
    Lansdown MR; Nash HL; Preston PR; Wallis DI
    Br J Pharmacol; 1979 May; 66(1):80P-81P. PubMed ID: 454965
    [No Abstract]   [Full Text] [Related]  

  • 31. [Comparative anorexigenic activity and other pharmacological properties of quipazine and its N-acyl derivatives].
    Trubitsyna TK; Asnina VV; Mashkovskiĭ MD
    Farmakol Toksikol; 1986; 49(1):44-9. PubMed ID: 3948987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Substituted piperazines as central serotonin agonists: comparative specificity of the postsynaptic actions of quipazine and m-trifluoromethylphenylpiperazine.
    Fuller RW; Snoddy HD; Mason NR; Hemrick-Luecke SK; Clemens JA
    J Pharmacol Exp Ther; 1981 Sep; 218(3):636-41. PubMed ID: 6167711
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of two serotonin antagonists on prolactin and thyrotrophin secretion in man.
    Ferrari C; Paracchi A; Rondena M; Beck-Peccoz P; Faglia G
    Clin Endocrinol (Oxf); 1976 Sep; 5(5):575-78. PubMed ID: 991435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quipazine exacerbation of a hyperkinetic syndrome: involvement of brain dopamine and serotonin.
    Langlais PJ; Gabay S
    J Neurosci Res; 1977; 3(2):135-41. PubMed ID: 563925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Agonist and antagonist properties of serotonergic compounds in pigeons trained to discriminate either quipazine or L-5-hydroxytryptophan.
    Yamamoto T; Walker EA; Woods JH
    J Pharmacol Exp Ther; 1991 Sep; 258(3):999-1007. PubMed ID: 1890629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dissociation of systemic and central effects of neurotensin on the secretion of growth hormone, prolactin, and thyrotropin.
    Maeda K; Frohman LA
    Endocrinology; 1978 Nov; 103(5):1903-9. PubMed ID: 107023
    [No Abstract]   [Full Text] [Related]  

  • 37. The effects of metergoline and other serotonin receptor antagonists on serum corticosterone in rats.
    Fuller RW; Snoddy HD
    Endocrinology; 1979 Oct; 105(4):923-8. PubMed ID: 477605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative maturation of the regulation of prolactin and thyrotropin by serotonin and thyrotropin-releasing hormone in male and female rats.
    Becú D; Libertun C
    Endocrinology; 1982 Jun; 110(6):1879-84. PubMed ID: 6804214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The acute effects of 5HTP, fluoxetine and quipazine on insulin and glucagon release in the intact rat.
    Jacoby JH; Bryce GF
    Horm Metab Res; 1979 Feb; 11(2):90-4. PubMed ID: 312241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological evidence of an interaction between serotonergic and dopaminergic neurons in the control of prolactin secretion in male rats.
    Quattrone A; Schettini G; Di Renzo GF; Preziosi P
    Arch Int Pharmacodyn Ther; 1979 Mar; 238(1):42-9. PubMed ID: 485703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.